Report post
ARS Pharmaceuticals' SPRY stock review: Martyn Lucas Investor dissects fundamental & technical analysis. FDA's last-minute denial of neffy approval sparks debate. Cramer predicts $100B value post-approval. Allergists, parents react to EpiPen alternative's FDA rejection, highlighting unmet need. Stay tuned for updates.

The World's Leading Crypto Trading Platform

Get my welcome gifts